RCS - MyCelx Tech. Corp. - Contract Secured for PFAS Remediation System

Mycelx TechnologiesAnnouncement

24/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230124:nRSX6110Na&default-theme=true

RNS Number : 6110N  MyCelx Technologies Corporation  24 January 2023

24 January 2023

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Rental Contract Secured for PFAS Remediation System at Landfill

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water
and clean air technology company, is pleased to announce that it has secured a
paid 6-month trial for treatment of PFAS in the United States. PFAS, which
stands for per-fluoroalkyl and poly-fluoroalkyl compounds, are a collection of
long-lasting manmade toxic chemicals which present a global threat to human
health and the environment.

 

MYCELX has secured a contract for its fully containerized, mobile PFAS
remediation system which includes MYCELX infused cartridge filtration and
Performer™ media. The system will be utilized for treating PFAS contaminated
leachate from a solid waste landfill. The rental is expected to successfully
demonstrate the ability of the proprietary MYCELX technology to completely
remove all identified PFAS chemicals to non-detectable concentrations in a
single pass.

 

The revenue from this trial is not anticipated to alter management's revenue
expectations for the year.

 

Connie Mixon, CEO, commented:

 

"We are pleased to announce this promising paid trial. The award is further
proof of the strong momentum we are generating as a business in the PFAS
solutions market, building on the Company's success with its previous trial in
America and installations in Australia with an important distributor. In
addition, in scenarios of solid waste landfill, we continue to see a growing
demand for technologies that are able to treat the co-contaminants that are
present with PFAS.

 

As a Group, we are firmly focused on achieving greater market share in three
core areas; the Middle East, PFAS and REGEN. All of which we believe will be
key growth drivers for MYCELX in 2023. We look forward to updating all our
stakeholders on further corporate developments over the coming months."

 

For further information, please contact:

 

 MYCELX Technologies Corporation

 Connie Mixon, CEO                                  Tel: +1 888 306 6843

 Kim Slayton, CFO

 Canaccord Genuity Limited (Nomad and Sole Broker)

 Henry Fitzgerald-O'Connor                          Tel: +44 20 7523 8000

 Gordon Hamilton

 Celicourt Communications (Financial PR)

 Mark Antelme                                       Tel: +44 20 8434 2754

 Jimmy Lea

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKNBKCBKDQDB